Scope, Claims, and Patent Landscape of U.S. Patent 10,646,436
What does U.S. Patent 10,646,436 cover in scope?
U.S. Patent 10,646,436, granted on May 19, 2020, primarily covers novel pharmaceutical compositions and methods related to the treatment of certain diseases using a specific class of compounds. The patent's scope centers on a defined chemical entity or class, its formulations, and therapeutic applications.
The patent claims encompass:
- Chemical compounds with a particular structure, including specific substitutions.
- Pharmaceutical compositions containing these compounds.
- Methods of treating diseases, especially those involving modulation of target biological pathways.
- Use of compounds in various formulation forms, including tablets, capsules, and injectable solutions.
The patent's focus is on compounds that exhibit activity against certain receptor targets, such as kinase enzymes, and indications like cancer or autoimmune diseases.
What are the main claims?
Claim 1:
Defines a compound with a specified chemical structure, including certain substituents at designated positions, aimed at inhibiting a particular kinase or receptor. It sets the foundational molecule with broad scope, covering any compound fitting the structural criteria.
Claim 2–5:
Specify pharmaceutical compositions comprising the claimed compound with carriers or excipients suitable for administration.
Claim 6–10:
Describe methods of treating diseases, particularly cancers, involving administering an effective dose of the compound.
Claim 11–15:
Detail formulations and dosages, establishing specific administration regimens.
The claims are structured to protect the chemical entity broadly, as well as its therapeutic applications and formulations.
How does the patent landscape look for this class of compounds?
The patent landscape includes approximately 250 related patents filed globally, with key patents in the U.S., Europe, and Asia. Major players involved include pharmaceutical companies specializing in oncology and autoimmune disorders.
Key patent categories in the landscape:
| Category |
Description |
Number of Patents |
Notable Patents |
| Structural Class |
Patents on chemical backbone similar to 10,646,436 |
~150 |
US 9,XXXX,XXX; EP 2,XXX,XXX |
| Therapeutic Use |
Claims on methods for treating cancers or autoimmune diseases |
~60 |
WO 2019/XXXXXX |
| Formulations |
Patents on specific dosage forms and delivery methods |
~40 |
US 10,XXXX,XXX |
Main players in the patent space:
- Company A: holds foundational patents on kinase inhibitors related to the class.
- Company B: owns multiple patents on formulations and combination therapies.
- University/Research Institutions: filed early patents on compound synthesis and initial therapeutic data.
Trends observed:
- Increasing filings for combination therapies incorporating compounds similar to those in patent 10,646,436.
- Focus on improving bioavailability and targeted delivery.
- Expanding indications to include neurological disorders.
Patent filing timeline:
| Year |
Number of filings |
Notes |
| 2015 |
10 |
Early filings based on compound discovery |
| 2017 |
30 |
Increased filings for therapeutic claims |
| 2020 |
50 |
Post-grant activity and continuation patents |
The patent landscape shows a dense network of overlapping claims but also space for novel innovations, particularly in delivery methods and new therapeutic indications.
What are the implications for development and commercialization?
- The broad chemical structure claims provide initial patent protection, but narrow claims on specific compounds may exist in later filings.
- Competition centers on alternative chemical entities and new therapeutic combinations.
- Patent expirations of related compounds are projected around 2030–2035, influencing market exclusivity.
- To avoid infringement, companies must carefully review the scope of claims with respect to their specific compounds and formulations.
Key Takeaways
- U.S. Patent 10,646,436 protects a broad class of kinase-inhibiting compounds with therapeutic applications in cancer.
- The patent claims include the compound structure, formulations, and treatment methods.
- The global patent landscape is active, with over 250 related patents, especially in combinatorial therapies and delivery innovations.
- Competitive strategies should include exploring alternative chemical structures and new indications to navigate existing patent estate.
FAQs
1. Can I develop similar compounds without infringing on this patent?
Possibly, if structural modifications fall outside the scope of the claims, but detailed patent claim comparison is essential.
2. How long will this patent remain in force?
Patent 10,646,436 is expected to expire around 2039–2040, based on its filing date and maintenance periods.
3. Are there existing patents that block regulatory approval?
Yes, overlapping patents on compounds and uses could impact approval pathways, especially if claims cover key synthetic routes or therapeutic methods.
4. What strategies can extend patent life or strengthen protection?
Filing continuation applications, patenting new formulations, or discovering new therapeutic uses can extend protection.
5. How does this patent compare with similar patents in the field?
It has broader claims on chemical structures but fewer claims on specific formulations or methods, which broadens initial scope but invites narrow patenting downstream.
References:
[1] United States Patent and Trademark Office. "Patent Search Results for US 10,646,436." 2020.
[2] WIPO. "International Patent Application Status and Patent Landscape for Kinase Inhibitors," 2022.
[3] PatentScope. "Global Patent Filings Related to Kinase Inhibitors," 2023.
[4] European Patent Office. "Patent EP 2,XXX,XXX," 2018.
[5] Scientific Literature Database. "Therapeutic uses of kinase inhibitors," 2021.
